natgillin/translations-raw huggingface dataset:
a) amoxicillin 1 g to gange daglig + clarithromycin 500 mg to gange daglig b) clarithromycin 250 mg to gange daglig + metronidazol 400- 500 mg to gange daglig c) amoxicillin 1 g to gange daglig + metronidazol 400- 500 mg to gange daglig.
The recommended dose is 30 mg lansoprazole 2 times daily for one week in combination with one of the following three combinations: a) amoxicillin 1 g twice daily + clarithromycin 500 mg twice daily, b) clarithromycin 250 mg twice daily + metronidazole 400-500 mg twice daily, c) amoxicillin 1 g twice daily + metronidazole 400-500 mg twice daily.
Officielle lokale retningslinjer bør tages i betragtning (f. eks. nationale anbefalinger) med hensyn til bakterieresistens og den passende anvendelse og ordinering af antibakterielle midler.
Consideration should be given to official local guidance (e. g. national recommendations) regarding bacterial resistance and the appropriate use and prescription of antibacterial agents.
Zollinger- Ellison Syndrome:
Zollinger-Ellison Syndrome:
Lansoprazol anbefales ikke til brug hos børn grundet utilstrækkelige data om sikkerhed og effektivitet.
Lansoprazole is not recommended for use in children due to insufficient data on safety and efficacy.
Grundet forsinket elimination af lansoprazol hos de ældre, kan det være nødvendigt at indgive behandlingen i doser på 15- 30 mg, justeret efter individuelle krav.
Due to delayed elimination of lansoprazole in the elderly it may be necessary to administer the treatment in doses of 15-30 mg adjusted to individual requirements.
Samtidig indtagelse af mad forsinker og nedsætter absorptionen af lansoprazol.
The capsules may be emptied, but the contents may not be chewed or ground. Concomitantly taken food slows down and reduces the absorption of lansoprazole.
4. 4 Særlige advarsler og forsigtighedregler vedrørende brugen
4.4 Special warnings and precautions for use
Refluks øsofagitis udviser måske ikke som ulceration og/ eller visuel beskadigelse, hvorfor endoskopi alene i visse tilfælde ikke er tilstrækkeligt.
Reflux oesophagitis may not present, as ulceration and/ or visual damage, therefore in certain cases endoscopy alone may not be sufficient.
4. 2 Dosering og indgivelsesmåde)
(See Section 4.2 Posology and Method of Administration)
9 følgende udtalelse analogt med omeprazol.
9 Lansoprazole has similar mechanism of action to omeprazole and both increase gastric pH, the following statement is made by analogy to omeprazole.
Nedsat gastrisk aciditet grundet lansoprazol øger øger gastriske ællinger af bakterier, der normalt er tilstede i mave- tarmkanalen.
Decreased gastric acidity due to lansoprazole increases gastric counts of bacteria normally present in the gastrointestinal tract.
Hos patienter, der lider af gastro- duodenale ulcera, bør muligheden for H. pylori infektion som en ætiologisk faktor overvejes.
Patients suffering from gastro-duodenal ulcers, the possibility of H. pylori infection as an etiological factor should be considered.
Hvis der forekommer synsforstyrrelser under langtidsbrugen (> 1 år), bør indtagelse af lægemidlet straks ophøre, og en oftalmolog bør rådspørges.
If visual disturbances occur during long-term use (> 1 year), intake of the medicine should immediately be stopped and an ophthalmologist should be consulted.
Da dette product indeholder sukrose, bør patienter med sjældne arvelige problemer som intolerance over for fruktose, glukose- galaktose malabsorption eller sukrase- isomaltase insufficiens ikke tage dette lægemiddel.
Since this product contains sucrose, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Aktive substanser forbundet med cytochrom P450 Da lansoprazol bliver metaboliseret via et lægemiddelmetaboliserende enzymsystem forbundet med cytochrom P450 (CYP2C19 og CYP3A4), er interaktioner med aktive substanser, der metaboliseres via det samme enzymsystem, mulige.
Active substances associated with cytochrome P450 As lansoprazole is metabolised via a drug metabolising enzyme system associated with cytochrome P450 (CYP2C19 and CYP3A4), interactions with active substances metabolised via the same enzyme system are possible.
Aktive substanser, der hæmmer CYP2C19 Aktive substanser, der hæmmer CYP2C19 kan øge plasmakoncentrationen af lansoprazol.
Active substances, which inhibit CYP2C19 Active substances, which inhibit CYP2C19 may increase the plasma concentration of lansoprazole.
Fluvoxamin, en hæmmer af CYP2C19, øgede plasmakoncentrationerne af lansoprazol op til 4 gange.
Fluvoxamine, an inhibitor of CYP2C19, increased the plasma concentrations of lansoprazole up to 4- fold.
Aktive substanser, der hæmmer CYP3A4 Aktive substanser, der hæmmer CYP3A4, såsom ketokonazol, itraconazol, proteasehæmmere, makrolider etc., kan mærkbart øge plasmakoncentrationerne af lansoprazol.
Active substances, which inhibit CYP3A4 Active substances, which inhibit CYP3A4 such as ketokonazole, itraconazole, protease inhibitors, macrolides etc may markedly increase the plasma concentrations of lansoprazole.
Ketoconazol og itraconazol Absorptionen af ketoconazol og itraconazol fra mave- tarmkanalen forstærkes ved tilstedeværelsen af mavesyre.
Ketoconazole and itraconazole The absorption of ketoconazole and itraconazole from the gastrointestinal tract is enhanced by the presence of gastric acid.
Dette resulterer i sub- terapeutiske koncentrationer af ketokonazol og itrakonazol, og kombinationen bør undgås.
This result in sub-therapeutic concentrations of ketokonazole and itrakonazole and the combination should be avoided.
Virkningen kan også være tilstede, hvis lansoprazol kombineres med andre aktive substanser med pH- afhængig absorption.
The effect may also be present if lansoprazole is combined with other active substances with pH dependent absorption.
Digoxin Samtidig indgivelse af lansoprazol og digoxin kan lede til øgede plasmaniveauer af digoxin.
Digoxin Coadminitration of lansoprazole and digoxin may lead to increased digoxin plasma levels.
Aktive substanser, der metaboliseres af CYP3A4 Lansoprazol kan anledning til øgede plasmakoncentrationer af aktive substanser, der metaboliseres af CYP3A4.
Active substances metabolised by CYP3A4 Lansoprazole may give rise to increased plasma concentrations of active substances metabolised by CYP3A4.
10 Samtidig administration af lansoprazol øger plasmakoncentrationerne af tacrolimus (et CYP3A og P - gp substrat).
10 Tacrolimus Co-administration of lansoprazole increases the plasma concentrations of tacrolimus (a CYP3A and P- gp substrate).
Carbamazepin Der tilrådes forsigtighed uder samtidig behandling med carbamazepin (et CYP3A substrat) og lansoprazol.
Carbamazepine Caution is advised during co-treatment with carbamazepine (a CYP3A substrate) and lansoprazole.
Fenytoin Undersøgelser har vist, at dosis af fenytoin (et CYP2C19 og CYP2C9 substrat) måske må nedsættes, når det gives samtidig med lansoprazol.
Phenytoin Studies have shown that the dose of phenytoin (a CYP2C19 and CYP2C9 substrate) may have to be reduced when administered concomitantly with lansoprazole.
Warfarin Forsigtighed og øget monitoreringshyppighed tilrådes ved indledning af aslutning af samtidig behandling med lansoprazol hos patienter, der behandles med warfarin.
Warfarin Caution and increased monitoring frequency is advised when initiating or ending lansoprazole co- treatment in patients treated with warfarin.
Teofyllin Lansoprazol giver en 14% reduktion i plasmakoncentrationerne af teofyllin.
Theophyllin Lansoprazole gives a 14% reduction in the plasma concentrations of theophyllin.
Antacider og sukralfat kan nedætte biotilgængeligheden for lansoprazol.
Antacids and sucralfate may decrease the bioavailabilty of lansoprazole.
Det er blevet set, at lansoprazol hæmmer transportproteinet P- glycoprotein (P- gp) in vitro.
Lansoprazole has been observed to inhibit the transport protein, P-glycoprotein (P-gp) in vitro.
Det kan ikke udelukkes, at lansoprazol kan påvirke transport via dette protein og give anledning til øgede plasmakoncentrationer af P- gp substrater såsom digoxin.
It may not be excluded that lansoprazole may affect transport via this protein giving rise to increased plasma concentrations of P-gp substrates such as digoxin.
Følgende interaktioner mellem lansoprazol og et/ to antibiotika anvendt ved udryddelsesbehandling er hidtil blevet fundet:
The following interactions between lansoprazole and one/ two antibiotics used in eradication therapy have been found so far:
Øgede plasmaniveauer af en clarithromycin metabolit med 16%; øget biotilgænglighed for lansoprazol med 19% op til 32%
Increased plasma levels of a clarithromycin metabolite by 16%; increased bioaivalability of lansoprazole by 19% up to 32%
lansoprazol + amoxicillin lansoprazol + metronidazol
11 lansoprazole + amoxicillin lansoprazole + metronidazole
30 mg + 1000 mg 3 gange/ dag i 5 dage Endnu ikke underøgt
30 mg + 1000 mg 3 times/ day for 5 days Not yet investigated
Nedbremser optagelsen af amoxicillin
Decelerates uptake of amoxicillin
11 lansoprazol + clarithromycin + amoxicillin
lansoprazole + clarithromycin + amoxicillin
Øger biotilgængeligheden og halveringstiden for lansoprazol med hver 30%; øgede plasmaniveauer af en clarithromycin metabolit med 30%
Increase bioaivalability and half-life of lansoprazole by 30% each; increased plasma levels of a clarithromycin metabolite by 30%
* Virkningerne af clarithromycin på farmakokinetikken for lansoprazol er sandsynligvis afhængig af patientens CYP2C19 genotype.
* The effects of clarithromycine on the pharmacokinetics of lansoprazole are likely to be dependent on the patient’ s CYP2C19 genotype.
Dyreundersøgelser indikerer ikke direkte eller indirekte skadelige virkninger med hensyn til graviditet, embryonal/ føtal udviklin, parturition eller postnatal udvikling.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/ fetal development, parturition or postnatal development.
4. 7 Anvendelsen af lansoprazol under graviditet anbefales ikke.
The use of lansoprazole during pregnancy is not recommended.
En beslutning om afbryde amning eller at fortsætte/ afbryde behandling med lansoprazol bør tages, idet fordelen ved amning for barnet og fordelen ved behandling med lansoprazol for kvinden bør tages i betragtning.
A decision on whether to continue/ discontinue breast-feeding or to continue/ discontinue therapy with lansoprazole should be made taking into account the benefit of breast-feeding to the child and the benefit of lansoprazole therapy to the woman.
4. 8 Virkninger på evnen til at føre motorkøretøj eller betjene maskiner
4.7 Effects on ability to drive and use machines
Bivirkninger Følgende bivirkninger er blevet observeret under behandling med lansoprazol med følgende hyppigheder:
The following undesirable effects have been observed during treatment with lansoprazole with the following frequencies:
Almindelig (> 1/ 100, < 1/ 10), ualmindelig (> 1/ 1, 000, < 1/ 100), sjælden (> 1/ 10, 000, < 1/ 1, 000), meget sjælden (< 1/ 10, 000) inklusive isolerede rapporter.
Common (> 1/ 100 ,< 1/10), uncommon (> 1/ 1,000 ,< 1/100), rare (> 1/ 10,000, < 1/ 1,000), very rare (< 1/ 10,000) including isolated reports.
Almindelig (1/ 100, < 1/ 10)
Common (1/ 100, < 1/ 10)
Ualmindelig (> 1/ 1000, < 1/ 100)
Uncommon (> 1/ 1000, < 1/ 100)
Sjælden (> 1/ 10000, < 1/ 1000)
Rare (> 1/ 10000, < 1/ 1000)
Meget sjælden (< 1/ 10000) inklusive isolerede rapporter
Very rare (< 1/ 10000) including isolated reports
Gastrointestinal e forstyrrelser
Gastrointestinal disorders
Opkastning, kvalme, diaré, mavepine, konstipation, flatulens og dyspepsi.
Vomiting, nausea, Dry mouth or diarrhea, stomach throat and ache, constipation, anorexia. flatulence and dyspepsia.
Tørhed i mund eller hals og anorexi.
Pancreatitis, candidiasis of oesophagus and glossitis.
Pancreatitis, candidiasis Colitis, stomatitis og i øsofagus og glossitis. sort tunge.
Colitis, stomatitis and black tongue.
Forstyrrelser i Eczema, urticaria hud og og kløen. subkutant væv
Eczema, urticaria and itching.
Erythema multiforme, Stevens- Johnson Petechia, hårtab, syndrome og toksisk hyperhidrosis og epidermal nekrolyse. purpura.
Erythema multiforme, Petechia, hair loss, hyperhidrosis and purpura.
Forstrelser i Hovedpine og nervesystemet svimmelhed.
Stevens-Johnson syndrome and toxic epidermal necrolysis.
Hepatobiliære forstyrrelser
Nervous system disorders
Øgning af niveauerne for leverenzymer.
Headache and dizziness.
Hepatitis og icterus
Depression, hallucination, confusion, insomnia, somnolence, drowsiness, vertigo, tremor and paresthesia, restlessness.
12
Hepatobiliary disorders Renal and urinary disorders
Renale og urinvejsmæssig e forstyrrelser
Increase in liver enzyme levels.
Interstitiel nephritis.
Hepatitis and icterus Interstitial nephritis.
Forstyrrelser i blod og lymfesystem Kardiale forstyrrelser Vaskulære forstyrrelser
Blood and lymphatic system disorders Cardiac disorders Vascular disorders
Thrombocytopeni, Agranulocytose. eosinofili, pancytopeni, anæmi og leukopeni.
Thrombocytopenia, eosinophilia, pancytopenia, anemia and leucopenia.
Perifert ødem.
Agranulocytosis.
Muskel - og ledsmerter.
Muscle and joint pain.
Øjen - og smagsforstyrrel ser
Eye and taste disorders
Smagsforstyrrel Visuelle forstyrrelser. ser.
Visual disturbances.
Almene forstyrrelser
General disorders
Fatigue
Fatigue
Anafylaktisk shock, impotens og almen utilpashed
Angioedema, bronchial Anaphylactic shock, constriction, fever. impotence and general malaise
Øgning i cholesterol - og triglyceridniveauer.
Increase in cholesterol and triglyceride levels.
4. 9 Overdosering
13 4.9 Overdose
4. 8.
Possible symptoms of lansoprazole overdose can be expected to be similar with adverse drug reactions listed in section 4.8.
Det hæmmer slutstadiet af dannelsen af mavesyre ved at hæmme aktiviteten af H+/ K+ ATPase i mavens parietalceller.
It inhibits the final stage of gastric acid formation by inhibiting the activity of H+/ K+ ATPase of the parietal cells in the stomach.
Hæmninger er dosisafhængig og reversibel, og virkningen gælder både basal og stimuleret sekretion af mavesyre.
The inhibition is dose- dependent and reversible, and the effect applies to both basal and stimulated secretion of gastric acid.
Lansoprazol er koncentreret i parietalcellerne og bliver aktiv i deres syrlige miljø, hvorefter det reagerer med sulfydrylgruppen i H+/ K+ATPase, hvilket medfører hæmning af enzymaktiviteten.
Lansoprazole is concentrated in the parietal cells and becomes active in their acidic environment, whereupon it reacts with the sulphydryl group of H+/ K+ATPase causing inhibition of the enzyme activity.
En enkelt oral dosis på 30 mg hæmmer pentagastrin- stimuleret mavesyresekretion med omkring 80%.
A single oral dose of 30 mg inhibits pentagastrin-stimulated gastric acid secretion by about 80%.
Det har en
After repeated daily administration for seven days, about 90% inhibition of gastric acid secretion is achieved.
13 korresponderende virkning på den basale sekretion af mavesyre.
It has a corresponding effect on the basal secretion of gastric acid.
5. 1 Farmakokinetiske egenskaber
5.2 Pharmacokinetic properties
Lansoprazol bliver hurigt inaktiveret a mavesyren og gives derfor som entero- coated granulat i gelatinekapsler.
Lansoprazole is rapidly inactivated by gastric acid and consequently administered as enteric-coated granules in gelatin capsules.
CYP2C19 er undergivet genetisk polymorfisme, og 2- 6% af populationen, kaldet dårlige metabolisatorer (PM’ er), er homozygote for en mutant CYP2C19 allele og mangler derfor et funktionelt CYP2C19 enzym.
CYP2C19 is subject to genetic polymorphism and 2-6% of the population, called poor metabolisers (PMs), are homozygote for a mutant CYP2C19 allele and therefore lacks a functional CYP2C19 enzyme.
Eksponeringen af lansoprazol er adskillige gange højere hos PM’ er end hos ekstensive metabolisatorer (EM’ er).
The exposure of lansoprazole is several-fold higher in PMs than in extensive metabolisers (EMs).
Tre metabolitter er blevet identificeret i plasma:
Three metabolites
Sulfonen, 5- hydroxy lansoprazol og sulfiden.
14 have been identified in the plasma: the sulphone, 5-hydroxy lansoprazole and the sulphide.
5- hydroxysulfon, 5- hydroxysulfid og 5- hydroxylansoprazol.
5- hydroxy sulphone, 5-hydroxy sulphide and 5-hydroxy lansoprazole.
Non- kliniske data afslører ikke nogen særlig fare for mennesker baseret på konventionelle undersøgelser afsikkerhedfarmakologi, gentagen dosis toksicitet, toksicitet ved reproduktion eller genotoksicitet.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, toxicity to reproduction or genotoxicity.
I to carcinogenicitetsundersøgelser på rotter frembragte lansoprazol dosis- relateret gastrisk ECL cellehyperplasi og ECL cellecarcinoider forbundet med hypergastrinæmi grundet hæmning af syresekretion.
In two rat carcinogenicity studies, lansoprazole produced dose-related gastric ECL cell hyperplasia and ECL cell carcinoids associated with hypergastrinaemia due to inhibition of acid secretion.
I carcinogenicitetsundersøgelser hos mus udvikledes dosis- relateret gastrisk ECL cellehyperplasi såvel som levertumorer og adenom af rete testis.
In mouse carcinogenicity studies dose-related gastric ECL cell hyperplasia developed as well as liver tumours and adenoma of rete testis.
14 6. 1 Fortegnelse over hjælpestoffer
6.1 List of excipients
Sukkerkugler (sukrose og majsstivelse) Natriumlaurylsulfat Meglumin Mannitol Hypromellose Macrogol Talkum Polysorbate 80 Titaniumdioxid (E171) Metakrylsyre- ethylakrylat copolymer, 1: 1, dispersion 30%
Sugar spheres(sucrose and maize starch) Sodium laurilsulphate Meglumine Mannitol Hypromellose Macrogol Talc Polysorbate 80 Titanium dioxide (E171) Methacrylic Acid-Ethyl Acrylate Copolymer, 1:1, Dispersion 30%
Gelatine Titaniumdioxid (E171) Quinolin gul (E104) – kun 15 mg kapsler
Gelatin Titanium dioxide (E171) Quinoline yellow (E104) – only 15 mg capsules
Al/ Al (OPA/ Al/ PVC // PVC/ Al/ PET) - blister
Al/ Al (OPA/ Al/ PVC/ /PVC/ Al/ PET) blister
7, 10, 10x1, 14, 14x1, 20, 28, 28x1, 30, 30x1, 56, 56x1, 60, 98, 98x1, 100 og 100x1 kapsler
7, 10, 10x1, 14, 14x1, 20, 28, 28x1, 30, 30x1, 56, 56x1, 60, 98, 98x1, 100 and 100x1 capsules
Ikke alle pakningsstørrelser bliver muligvis markedsført.
Not all pack sizes may be marketed.
6. 6 Eventuelle instruktioner vedørende anvendelse og håndtering
6.6 Special precautions for disposal
Ingen særlige instruktioner.
No special requirements.
ratiopharm GmbH Graf- Arco- Strasse 3 D- 89079 Ulm Tyskland
ratiopharm GmbH Graf-Arco-Strasse 3 D-89079 Ulm Germany
DATO FOR FØRSTE TILLADELSE/ FORNYELSE AF TILLADELSEN
DATE OF FIRST AUTHRORISATION/ RENEWAL OF AUTHORISATION
16 ETIKETTERING
16 LABELLING
17 OPLYSNINGER, DER SKAL FREMGÅ PÅ YDEREMBALLAGEN OG DEN UMIDDELBARE EMBALLAGE
17 PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
< Lansoprazol AbZ og tilknyttede navne (se Bilag I) 15 mg gastro- resistent hård kapsel > lansoprazol
< Lansoprazol AbZ and associated names (see Annex I) 15 mg, gastro-resistant capsules, hard > lansoprazole
[se Bilag I – udfyldes nationalt]
[see Annex I - to be completed nationally]
ANGIVELSE AF AKTIV SUBSTANS( ER)
STATEMENT OF ACTIVE SUBSTANCE(S)
EHver gastro- resistennt kapsel indeholder 15 mg lansoprazol
Each gastro-resistant capsule contains 15 mg lansoprazole
Indeholder også sukrose (sukker).
Also contains sucrose (sugar).
7 gastro- resistente hårde kapsler 14 gastro- resistente hårde kapsler 28 gastro- resistente hårde kapsler 56 gastro- resistente hårde kapsler 98 gastro- resistente hårde kapsler
7 Gastro-resistant hard capsules 14 Gastro-resistant hard capsules 28 Gastro-resistant hard capsules 56 Gastro-resistant hard capsules 98 Gastro-resistant hard capsules
ADMINISTRATIONSMÅDE OG RUTE( R)
METHOD AND ROUTE(S) OF ADMINISTRATION
Opbevares i oiginalemballagen for at beskytte mod fugt.
Store in the original package in order to protect from moisture.
ratiopharm GmbH Graf- Arco- Strasse 3 D- 89070 Ulm Tyskland
ratiopharm GmbH Graf-Arco-Strasse 3 D-89079 Ulm Germany
MARKEDSFØRINGSTILLADELSESNUMMER/ NUMRE
MARKETING AUTHORISATION NUMBER(S)
[udfyldes nationalt
[to be completed nationally]
ALMEN KLASSIFIKATION FOR LEVERING
GENERAL CLASSIFICATION FOR SUPPLY
ANVISNNGER FOR BRUGEN
INSTRUCTIONS ON USE
Lægemiddel underkastet receptpligt.
Acid repressive gastrointestinal-therapeutic
19 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
19 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
< Lansoprazol AbZ og tilknyttede navne (se Bilag I) 15 mg gastro- resistente hårde kapsler >
< Lansoprazol AbZ and associated names (see Annex I) 15 mg, gastro-resistant capsules, hard >
20 OPLYSNINGER, DER SKAL FREMGÅ PÅ YDEREMBALLAGEN OG DEN UMIDDELBARE EMBALLAGE
20 PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
< Lansoprazol AbZ og tilknyttede navne (se Bilag I) 30 mg gastro- resistent hård kapsel > lansoprazol
< Lansoprazol AbZ and associated names (see Annex I) 30 mg, gastro-resistant capsules, hard > lansoprazole
Hver gastro- resistent kapsel indeholder 30 mg lansoprazol
Each gastro-resistant capsule contains 30 mg lansoprazole
Læ indlægssedlen inden anvendelsen.
Read the package leaflet before use.
SÆRLIGE OPBEVAINGSFORHOLD
SPECIAL STORAGE CONDITIONS
Syrerepressiv gastrointestinal behandling
Acid repressive gastrointestinal-therapeutic
22 MINIMUMOPLYSNINGER DER FREMSTÅR PÅ BLISTERS ELLER STRIMLER
22 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
< Lansoprazol AbZ og tilknyttede navne (se Bilag I) 30 mg gastro- restistente hårde kapsler >
< Lansoprazol AbZ and associated names (see Annex I) 30 mg, gastro-resistant capsules, hard >
23 INDLÆGSSEDDEL
23 PACKAGE LEAFLET
24 INDLÆGSSEDDEL
24 PACKAGE LEAFLET:
< Lansoprazol AbZ og tilknyttede navne (se Bilag I) 15 mg gastro- resistente hårde kapsler > Lansoprazol
< Lansoprazol AbZ and associated names (see Annex I) 15 mg, gastro-resistant capsules, hard > Lansoprazol
skade dem, selvom de fremviser symptomer, der ligner dine.
if their symptoms are the same as yours.
- Hvis nogen af bivirkningerne bliver alvorlige, eller hvis du lægger mærke til nogen
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
bivirkninger, der ikke er angivet i denne indlægsseddel, så fortæl det til din læge eller apotek.
please tell your doctor or pharmacist.
Hvad er Lansoprazol AbZ, og hvad anvendes det til.
What Lansoprazol AbZ is and what it is used for 2.
Inden du tager Lansoprazol AbZ 3.
Before you take Lansoprazol AbZ 3.
Hvorledes skal Lansoprazol AbZ tages 4.
How to take Lansoprazol AbZ 4.
Opbevaring af Lansoprazol AbZ 6.
How to store Lansoprazol AbZ 6.